File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Modulation of intra-pulmonary TGF-β expression by mycophenolate mofetil in lupus prone MRL/lpr mice

TitleModulation of intra-pulmonary TGF-β expression by mycophenolate mofetil in lupus prone MRL/lpr mice
Authors
KeywordsCytokine
Lung
MRL/lpr mice
Mycophenolate mofetil
Systemic lupus erythematosus
TGF-β
Issue Date2005
PublisherSage Publications Ltd. The Journal's web site is located at http://lup.sagepub.com
Citation
Lupus, 2005, v. 14 n. 8, p. 583-592 How to Cite?
AbstractWe investigated the expression profile of inflammatory cytokines in the lung of lupus-prone MRL/lpr mice and evaluated the therapeutic potential of mycophenolate mofetil (MMF) in reducing pulmonary cytokines in active lupus. Eight-week old female MRL/lpr mice (n = 20) were treated with MMF in vehicle by oral gavage. Disease control MRL/lpr mice (n = 30) or normal control MRL mice (n = 20) received vehicle alone. The mice were sacrificed after eight or 12 weeks of treatment. Gene expression and protein synthesis of IL-1β, MCP-1 and TGF-β1 in lung tissues were determined. We found an increase in the gene expression of IL-1β, MCP-1 and TGF-β1 in lung tissues of untreated MRL/lpr mice compared with MRL mice at either 16 weeks or 20 weeks of age. MMF treatment significantly prolonged the survival of MRL/lpr mice, down-regulated the gene expression of IL-1β, MCP-1 and TGF-β1 in lung tissues at the end of eight or 12 weeks of treatment. Protein synthesis of TGF-β1 was decreased following eight weeks of MMF treatment. We conclude that MMF treatment can reduce the TGF-β1 gene expression and protein synthesis in lung tissues of lupus-prone mice. Our findings provide experimental data suggesting a beneficial potential of MMF therapy in pulmonary involvement of lupus. © 2005 Edward Arnold (Publishers) Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/162881
ISSN
2015 Impact Factor: 2.118
2015 SCImago Journal Rankings: 0.878
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorGuo, Hen_US
dc.contributor.authorLeung, JCKen_US
dc.contributor.authorChan, LYYen_US
dc.contributor.authorLui, SLen_US
dc.contributor.authorTsang, AWLen_US
dc.contributor.authorLai, KNen_US
dc.date.accessioned2012-09-05T05:24:42Z-
dc.date.available2012-09-05T05:24:42Z-
dc.date.issued2005en_US
dc.identifier.citationLupus, 2005, v. 14 n. 8, p. 583-592en_US
dc.identifier.issn0961-2033en_US
dc.identifier.urihttp://hdl.handle.net/10722/162881-
dc.description.abstractWe investigated the expression profile of inflammatory cytokines in the lung of lupus-prone MRL/lpr mice and evaluated the therapeutic potential of mycophenolate mofetil (MMF) in reducing pulmonary cytokines in active lupus. Eight-week old female MRL/lpr mice (n = 20) were treated with MMF in vehicle by oral gavage. Disease control MRL/lpr mice (n = 30) or normal control MRL mice (n = 20) received vehicle alone. The mice were sacrificed after eight or 12 weeks of treatment. Gene expression and protein synthesis of IL-1β, MCP-1 and TGF-β1 in lung tissues were determined. We found an increase in the gene expression of IL-1β, MCP-1 and TGF-β1 in lung tissues of untreated MRL/lpr mice compared with MRL mice at either 16 weeks or 20 weeks of age. MMF treatment significantly prolonged the survival of MRL/lpr mice, down-regulated the gene expression of IL-1β, MCP-1 and TGF-β1 in lung tissues at the end of eight or 12 weeks of treatment. Protein synthesis of TGF-β1 was decreased following eight weeks of MMF treatment. We conclude that MMF treatment can reduce the TGF-β1 gene expression and protein synthesis in lung tissues of lupus-prone mice. Our findings provide experimental data suggesting a beneficial potential of MMF therapy in pulmonary involvement of lupus. © 2005 Edward Arnold (Publishers) Ltd.en_US
dc.languageengen_US
dc.publisherSage Publications Ltd. The Journal's web site is located at http://lup.sagepub.comen_US
dc.relation.ispartofLupusen_US
dc.rightsLupus. Copyright © Sage Publications Ltd.-
dc.subjectCytokine-
dc.subjectLung-
dc.subjectMRL/lpr mice-
dc.subjectMycophenolate mofetil-
dc.subjectSystemic lupus erythematosus-
dc.subjectTGF-β-
dc.subject.meshAnimalsen_US
dc.subject.meshChemokine Ccl2 - Genetics - Metabolismen_US
dc.subject.meshFemaleen_US
dc.subject.meshImmunosuppressive Agents - Pharmacologyen_US
dc.subject.meshInterleukin-1 - Genetics - Metabolismen_US
dc.subject.meshLung - Drug Effects - Metabolismen_US
dc.subject.meshLupus Erythematosus, Systemic - Etiology - Metabolismen_US
dc.subject.meshMiceen_US
dc.subject.meshMice, Inbred Mrl Lpren_US
dc.subject.meshMycophenolic Acid - Analogs & Derivatives - Pharmacologyen_US
dc.subject.meshRna, Messenger - Metabolismen_US
dc.subject.meshTransforming Growth Factor Beta - Genetics - Metabolismen_US
dc.subject.meshTransforming Growth Factor Beta1en_US
dc.titleModulation of intra-pulmonary TGF-β expression by mycophenolate mofetil in lupus prone MRL/lpr miceen_US
dc.typeArticleen_US
dc.identifier.emailLeung, JCK:jckleung@hku.hken_US
dc.identifier.emailLai, KN:knlai@hku.hken_US
dc.identifier.authorityLeung, JCK=rp00448en_US
dc.identifier.authorityLai, KN=rp00324en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1191/0961203305lu2170oaen_US
dc.identifier.pmid16175929-
dc.identifier.scopuseid_2-s2.0-24744437009en_US
dc.identifier.hkuros121468-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-24744437009&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume14en_US
dc.identifier.issue8en_US
dc.identifier.spage583en_US
dc.identifier.epage592en_US
dc.identifier.isiWOS:000231977900003-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridGuo, H=16236337600en_US
dc.identifier.scopusauthoridLeung, JCK=7202180349en_US
dc.identifier.scopusauthoridChan, LYY=8108378300en_US
dc.identifier.scopusauthoridLui, SL=7102379130en_US
dc.identifier.scopusauthoridTsang, AWL=7006979244en_US
dc.identifier.scopusauthoridLai, KN=7402135706en_US
dc.identifier.citeulike316812-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats